Literature DB >> 16505317

Course of disability and respiratory function in untreated late-onset Pompe disease.

M L C Hagemans1, W J C Hop, P A Van Doorn, A J J Reuser, A T Van der Ploeg.   

Abstract

Fifty-two untreated patients with late-onset Pompe disease completed questionnaires about their clinical condition and level of handicap at baseline and at 1-year (n = 41) and 2-year follow-ups (n = 40). During this period, declines in functional activities, respiratory function, handicap, and survival were recorded on a group level. This study illustrates the progressiveness of late-onset Pompe disease and indicates the need for close clinical follow-up of both children and adults with this disorder.

Entities:  

Mesh:

Year:  2006        PMID: 16505317     DOI: 10.1212/01.wnl.0000198776.53007.2c

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

1.  Therapeutic advances in the management of Pompe disease and other metabolic myopathies.

Authors:  Corrado Angelini; Anna Chiara Nascimbeni; Claudio Semplicini
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

Review 2.  Enzyme replacement therapy for Pompe disease.

Authors:  Corrado Angelini; Claudio Semplicini
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

3.  Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease.

Authors:  J C van der Meijden; D Güngör; M E Kruijshaar; A D J Muir; H A Broekgaarden; A T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2014-08-12       Impact factor: 4.982

4.  Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency.

Authors:  Andrea Vianello; Claudio Semplicini; Luciana Paladini; Alessandra Concas; Sabrina Ravaglia; Serenella Servidei; Antonio Toscano; Tiziana Mongini; Corrado Angelini; Elena Pegoraro
Journal:  Lung       Date:  2013-07-10       Impact factor: 2.584

5.  Enzyme replacement therapy in juvenile glycogenosis type II: a longitudinal study.

Authors:  Laura Deroma; Mattia Guerra; Annalisa Sechi; Giovanni Ciana; Giorgia Cisilino; Andrea Dardis; Bruno Bembi
Journal:  Eur J Pediatr       Date:  2014-01-07       Impact factor: 3.183

6.  Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study.

Authors:  Claudio Semplicini; Pascaline Letard; Marie De Antonio; Nadjib Taouagh; Barbara Perniconi; Françoise Bouhour; Andoni Echaniz-Laguna; David Orlikowski; Sabrina Sacconi; Emmanuelle Salort-Campana; Guilhem Solé; Fabien Zagnoli; Dalil Hamroun; Roseline Froissart; Catherine Caillaud; Pascal Laforêt
Journal:  J Inherit Metab Dis       Date:  2018-08-28       Impact factor: 4.982

Review 7.  Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.

Authors:  Benedikt Schoser; Andrew Stewart; Steve Kanters; Alaa Hamed; Jeroen Jansen; Keith Chan; Mohammad Karamouzian; Antonio Toscano
Journal:  J Neurol       Date:  2016-07-02       Impact factor: 4.849

8.  Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice.

Authors:  Richard L Sidman; Tatyana Taksir; Jonathan Fidler; Michael Zhao; James C Dodge; Marco A Passini; Nina Raben; Beth L Thurberg; Seng H Cheng; Lamya S Shihabuddin
Journal:  J Neuropathol Exp Neurol       Date:  2008-08       Impact factor: 3.685

9.  The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients.

Authors:  Carine I van Capelle; Nadine A M E van der Beek; Juna M de Vries; Pieter A van Doorn; Hugo J Duivenvoorden; Robert T Leshner; Marloes L C Hagemans; Ans T van der Ploeg
Journal:  J Inherit Metab Dis       Date:  2011-09-13       Impact factor: 4.982

10.  Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy.

Authors:  Juna M de Vries; Esther Kuperus; Marianne Hoogeveen-Westerveld; Marian A Kroos; Stephan C A Wens; Merel Stok; Nadine A M E van der Beek; Michelle E Kruijshaar; Dimitris Rizopoulos; Pieter A van Doorn; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Genet Med       Date:  2016-06-30       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.